Apigenin and Women’s Hormonal Health: Estrogen Receptor Activity, Menopause, and Fertility Considerations

Apigenin is a naturally occurring flavonoid concentrated in chamomile tea, parsley, and celery. As interest in plant-based compounds for hormonal support has grown, apigenin has attracted attention for two reasons: it can interact with estrogen receptors in laboratory models, and chamomile—its richest dietary source—has a long history of use in women’s health. For women navigating perimenopause, hormonal questions, or fertility concerns, understanding what apigenin actually does, and what the evidence genuinely supports, matters more than marketing claims.

This article examines current research on apigenin and women’s hormonal biology across three areas: its phytoestrogenic activity at estrogen receptors, human and clinical data on menopause symptom relief, and reproductive considerations drawn largely from animal models. Where findings are preliminary or come only from cell cultures, we say so plainly. Nothing here constitutes medical advice, and these statements have not been evaluated by the FDA.

Apigenin as a Phytoestrogen: What Estrogen Receptor Research Shows

Phytoestrogens are plant-derived compounds that can bind to and activate—or block—estrogen receptors (ERs). Apigenin belongs to this functional category, though its estrogenic potency is generally considered weaker than isoflavones like genistein. Research using cell-based models has investigated whether apigenin behaves as a selective estrogen receptor modulator (SERM), meaning it might activate certain ER-dependent pathways while opposing others, depending on the tissue. A 2017 study assessed apigenin and other major dietary flavonoids for potential SERM-like activity using two distinct cell models for proliferation and differentiation ^[3]. This type of dual activity is pharmacologically important because genuine SERMs can, in principle, be protective in some tissues while opposing estrogen in others—but whether apigenin achieves this in the human body at dietary or typical supplemental doses has not been established clinically.

More recent work has examined apigenin’s affinity for ESR1, the gene encoding estrogen receptor alpha (ERα), which drives a significant proportion of hormone-sensitive breast cancers. A 2026 integrated computational and cell-based study characterized apigenin as a dual inhibitor of both PARP1 and ESR1 ^[7]. The demonstrated binding to ERα helps explain both the potential interest in apigenin for hormonal applications and the caution warranted in hormone-sensitive clinical contexts. Importantly, binding affinity in a lab model does not automatically predict benefit or harm in a whole human system—these findings generate hypotheses that human trials would need to confirm.

Menopause Symptom Relief: Chamomile, Apigenin, and the Clinical Evidence

Chamomile (Matricaria chamomilla) is the most concentrated common dietary source of apigenin, and it has a documented history of use for women’s health across many cultures. A 2025 triple-blind clinical trial evaluated the efficacy and safety of a chamomile intervention in managing menopausal symptoms and found it to be effective compared to placebo, with a favorable safety profile ^[5]. This represents one of the more rigorous human-level data points linking apigenin-rich botanical use to menopausal outcomes.

An important caveat: chamomile contains multiple bioactive compounds beyond apigenin, including α-bisabolol, chamazulene, and various apigenin glycosides. The symptom-relief effects observed in that trial cannot be attributed to apigenin alone. Apigenin’s binding at GABA-A receptors—which underlies its known anxiolytic and sleep-onset effects—may contribute to relief from anxiety and sleep disruption that frequently accompany menopause, but isolating apigenin’s specific contribution within a whole chamomile preparation requires further targeted research.

Survey-based research has documented that botanical supplement use is common among peri- and postmenopausal women ^[1]. This pattern of use reflects real demand for non-pharmaceutical options during hormonal transition, and it underscores why rigorous clinical trials on safety and efficacy matter. Popular use does not equal proven benefit, and interactions with medications commonly prescribed in this age group deserve explicit evaluation.

Breast Cancer Context: Apigenin's Relationship with Hormone-Sensitive Cells

Because apigenin interacts with estrogen receptors, its behavior in hormone-sensitive cancer cells has been examined in several preclinical studies. A 2012 study found that apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors ^[2]. Medroxyprogesterone acetate is a synthetic progestin used in some hormone therapy regimens, and BT-474 is a HER2-positive, hormone receptor-positive cell line—the type that depends on hormone signaling to proliferate. The finding suggests apigenin may oppose hormone-driven tumor growth under at least some laboratory conditions.

A 2020 study examined apigenin’s effect on the full transcriptome of TNFα-activated MDA-MB-468 cells, a triple-negative breast cancer (TNBC) line lacking estrogen, progesterone, and HER2 receptors ^[4]. Apigenin modulated gene expression in this hormone-receptor-negative context, pointing to mechanisms beyond simple ERα binding. The 2026 dual PARP1/ESR1 inhibitor study ^[7] further positions apigenin as potentially relevant across multiple breast cancer subtypes through distinct molecular targets.

These are all preclinical findings. They do not establish that apigenin supplementation prevents or treats breast cancer in humans. Women with a personal or family history of hormone-receptor-positive breast cancer, or who are on anti-estrogen therapies, should discuss apigenin use with their oncologist before starting any supplement.

Fertility and Reproductive Considerations: Animal Data and Unanswered Questions

Apigenin’s reproductive profile is less well-characterized than that of isoflavones like genistein or daidzein. A 2025 study on bovine models examined how phytoestrogens modulate G protein-coupled receptors and regulate reproductive functions in animals ^[6]. The findings indicate that phytoestrogens can interact with hormone-signaling pathways involved in reproduction—including those relevant to follicular development and luteal function—in animal systems. This is mechanistically plausible given apigenin’s phytoestrogenic activity, but translating bovine reproductive data to human fertility is not straightforward.

No human clinical trials specifically examining apigenin’s effects on female fertility, ovulation, or menstrual cycle regularity have been identified in the current evidence base. The theoretical concern is that phytoestrogenic activity at supplemental doses could interfere with the precise hormonal signaling required for normal follicular development—a concern that has also been raised about high-dose isoflavone supplementation. Until human data exist, women who are actively trying to conceive should exercise caution with apigenin supplements above what is obtained from normal dietary intake and consult a reproductive endocrinologist or OB-GYN.

Drug Interactions and Safety for Women on Medications

Apigenin is a meaningful inhibitor of cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP3A4. These enzymes metabolize a wide range of medications that women in perimenopause and beyond commonly use. Warfarin is cleared through CYP2C9, and apigenin’s inhibition could theoretically elevate warfarin blood levels, increasing bleeding risk. Several statins use CYP3A4, as do some components of hormone therapy. Women on any of these medications should consult their prescribing physician before supplementing with apigenin.

Additionally, apigenin’s GABA-A receptor activity creates a potential for additive sedation when combined with benzodiazepines, prescription sleep medications, alcohol, or high-dose melatonin. For women in menopause who may already be using sleep aids to manage insomnia—a common symptom in this transition—this stacking risk is particularly relevant. The chamomile clinical trial ^[5] did not report serious adverse events, which is reassuring for normal chamomile tea consumption, but concentrated apigenin supplements deliver substantially higher doses and carry a different risk profile.

Dietary Apigenin vs. Supplements: A Practical Distinction

A cup of chamomile tea typically delivers roughly 2–10 mg of apigenin depending on steeping time and brand, while commonly available apigenin supplements provide 50–100 mg or more per capsule. The clinical trial on chamomile for menopause symptoms ^[5] used a whole chamomile preparation, not isolated apigenin—meaning its reassuring safety data applies to the botanical, not necessarily to high-dose isolated compound. Survey data confirm that botanical supplement use in menopausal women is substantial ^[1], yet research directly comparing outcomes between tea, whole-herb preparations, and isolated high-dose apigenin in this population is lacking.

For most healthy women obtaining apigenin through food, the phytoestrogenic effects are likely modest and broadly consistent with long-term traditional use of chamomile and parsley-containing diets. The mechanistic concerns about estrogen receptor activity, potential reproductive hormone interactions, and CYP enzyme inhibition become more clinically meaningful at supplemental doses. This distinction is important when interpreting the preclinical research and deciding whether and how to use apigenin products.

A Note on the Evidence

The human clinical evidence on apigenin specifically for women’s hormonal health is limited; the most relevant human trial studied chamomile extract—not isolated apigenin—for menopausal symptoms [PMID 39836709], and most mechanistic findings come from cell cultures and animal models that may not translate directly to human physiology. Women who are pregnant, actively trying to conceive, undergoing cancer treatment, or taking medications metabolized by CYP1A2, CYP2C9, or CYP3A4—including warfarin, certain statins, and oral hormonal medications—should consult a physician before using apigenin supplements.

Frequently Asked Questions

Does apigenin raise or lower estrogen levels in women?

Apigenin does not directly raise circulating estrogen in the way estrogen therapy would. It binds to estrogen receptors and may act as a weak phytoestrogen or SERM, potentially activating or modulating ER-dependent pathways depending on tissue context ^[3]. Whether this translates to measurable changes in women’s serum hormone levels at typical supplemental doses has not been established in human clinical trials.

Can apigenin help with hot flashes or other menopause symptoms?

A 2025 triple-blind clinical trial found that Matricaria chamomilla—the richest dietary source of apigenin—effectively managed menopausal symptoms compared to placebo, with a good safety profile ^[5]. However, chamomile contains numerous bioactive compounds beyond apigenin, so attributing the benefit specifically to apigenin would be premature. Dedicated human trials on isolated apigenin for menopause are needed before firm conclusions can be drawn.

Is apigenin safe for women with hormone-receptor-positive breast cancer?

This question requires an oncologist’s input, not a supplement label. Apigenin has shown inhibitory activity against ESR1 (estrogen receptor alpha) and hormone-sensitive cancer cell lines in laboratory studies [PMID 41495854, PMID 22569706], but these are preclinical findings that do not constitute clinical evidence of safety or efficacy. Its interactions with anti-estrogen therapies used in oncology are not well characterized in humans, making physician consultation non-negotiable.

Does apigenin affect fertility or the menstrual cycle?

Animal research shows that phytoestrogens, including apigenin-class compounds, can modulate reproductive hormone signaling pathways ^[6], but no human clinical trials examining apigenin’s effects on female fertility, ovulation, or menstrual regularity have been identified. The theoretical concern is interference with follicular development at higher supplemental doses. Women who are trying to conceive should discuss this with a reproductive specialist before supplementing.

Is it safe to drink chamomile tea daily for menopause support?

The 2025 clinical trial ^[5] found chamomile intervention to be safe and beneficial for menopausal symptoms in its study population, and daily chamomile tea is generally considered low-risk for healthy adults. Women on blood thinners, sedative medications, or hormone therapy should check with their doctor first, given apigenin’s inhibition of CYP2C9 and CYP3A4 and its additive potential with GABA-acting agents.

Can apigenin interact with hormone therapy or hormonal contraceptives?

Yes, this is a genuine concern. Apigenin inhibits CYP3A4 and CYP2C9—enzymes involved in metabolizing various hormonal medications, including certain oral contraceptives and hormone therapy components. Inhibiting these enzymes could theoretically alter drug levels in unpredictable ways. Women on any hormonal medication should consult their prescribing physician before adding an apigenin supplement to their routine.

References

1. Mahady GB et al. Botanical dietary supplement use in peri- and postmenopausal women. Menopause (New York, N.Y.) (2003). PMID 12544679
2. Mafuvadze B et al. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Hormones & cancer (2012). PMID 22569706
3. Lecomte S et al. Assessment of the potential activity of major dietary compounds as selective estrogen receptor modulators in two distinct cell models for proliferation and differentiation. Toxicology and applied pharmacology (2017). PMID 28396216
4. Bauer D et al. Effect of apigenin on whole transcriptome profile of TNFα-activated MDA-MB-468 triple negative breast cancer cells. Oncology letters (2020). PMID 32194710
5. Mohsenzadeh-Ledari F et al. Efficacy and safety of Matricaria chamomilla intervention in managing menopausal symptoms: a triple-blind clinical trial. Menopause (New York, N.Y.) (2025). PMID 39836709
6. Safdar M et al. Phytoestrogens Modulate Bovine G Protein-Coupled Receptors and Play a Critical Role in Regulating Reproductive Functions in Animals. Reproduction in domestic animals = Zuchthygiene (2025). PMID 40116542
7. Arora M et al. Integrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer. BMC pharmacology & toxicology (2026). PMID 41495854

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.